Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab

INTRODUCTION: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a rapid onset of action and sustained responses wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Spindeldreher, Sebastian, Maillère, Bernard, Correia, Evelyne, Tenon, Maxime, Karle, Anette, Jarvis, Philip, Kolbinger, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825325/
https://www.ncbi.nlm.nih.gov/pubmed/29392570
http://dx.doi.org/10.1007/s13555-018-0220-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825325/
https://www.ncbi.nlm.nih.gov/pubmed/29392570
http://dx.doi.org/10.1007/s13555-018-0220-y

Ejemplares similares